metformin has been researched along with Cell Transformation, Neoplastic in 45 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this review, current data was used to elucidate the mechanisms by which metformin hydrochloride exerts chemopreventive effects on colorectal cancer (CRC)." | 9.12 | Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer. ( Jaromy, M; Miller, JD, 2021) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 7.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| "Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile." | 5.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 5.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "In this review, current data was used to elucidate the mechanisms by which metformin hydrochloride exerts chemopreventive effects on colorectal cancer (CRC)." | 5.12 | Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer. ( Jaromy, M; Miller, JD, 2021) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 3.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| "Metformin, the first-line drug for treating diabetes, inhibits cellular transformation and selectively kills cancer stem cells in breast cancer cell lines." | 3.79 | Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2013) |
| " Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transformation and selectively kills cancer stem cells in four genetically different types of breast cancer." | 3.75 | Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. ( Hirsch, HA; Iliopoulos, D; Struhl, K; Tsichlis, PN, 2009) |
| "Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well." | 2.49 | Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013) |
| "Colorectal cancer is the third leading cause of cancer death in Japan and the United States and is strongly associated with obesity, especially visceral obesity." | 2.49 | Colon epithelial proliferation and carcinogenesis in diet-induced obesity. ( Endo, H; Hosono, K; Nakajima, A; Takahashi, H, 2013) |
| "Cancer cells in solid tumors are generally subjected to such harsh conditions; however, they manage to efficiently survive and proliferate." | 2.49 | The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all? ( Bonini, MG; Gantner, BN, 2013) |
| "Obesity is a known risk factor for many types of cancers and a number of endocrine factors, including adipokines and steroid hormones, are regulated by and regulate AMPK." | 2.49 | Endocrine-related cancers and the role of AMPK. ( Brown, KA; Samarajeewa, NU; Simpson, ER, 2013) |
| "Most breast cancer studies have focused on the intrinsic characteristics of breast tumor cells, including altered growth, proliferation, and metabolism." | 2.48 | Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. ( Claerhout, S; Mills, GB; Mitra, S; Stemke-Hale, K, 2012) |
| "Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing." | 2.48 | Endometrial carcinoma tumorigenesis and pharmacotherapy research. ( Fang, S; Huang, H; Shu, J; Teichman, PG; Xing, L, 2012) |
| "Preclinical data suggest that current breast cancer treatment strategies lead to CSC enrichment, contributing to chemotherapy and radiotherapy resistance, although a strong correlation with clinical parameters and prognosis is yet to be established." | 2.48 | The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. ( Economopoulou, P; Kaklamani, VG; Siziopikou, K, 2012) |
| "Metformin's molecular targets in cancer cells (e." | 2.47 | Metformin: multi-faceted protection against cancer. ( Bosch-Barrera, J; Cufí, S; Del Barco, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2011) |
| "Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile." | 1.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin treatment also significantly reduced tumor formation in vivo as well as protein expression of PCNA, Akt, Myc, and serine phosphorylation of the latter 2, which can be partially blocked by O/E α4 or sh-PP2Ac." | 1.51 | Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A. ( Jiang, W; Lin, X; Liu, J; Liu, S; Mao, X; Xu, L; Zhang, Z; Zhou, H; Zhou, X, 2019) |
| "Oral squamous cell carcinoma (OSCC) is the most common and aggressive epithelial tumor in the head and neck region with a rising incidence." | 1.51 | Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma. ( Cheng, B; Deng, M; Fan, Z; He, L; He, Y; Huang, Y; Ping, F; Tai, S; Xia, J; Zhang, C, 2019) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 1.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "Metformin is a widely prescribed drug for the treatment of type II diabetes." | 1.42 | Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat. ( Echeverria, D; Jiang, W; McGinley, JN; Thompson, HJ; Thompson, MD; Zhu, Z, 2015) |
| "Oncocytomas are predominantly benign neoplasms possessing pathogenic mitochondrial mutations and accumulation of respiration-defective mitochondria, characteristics of unknown significance." | 1.42 | The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. ( Aviv, H; Chan, CS; Ganesan, S; Hakimi, AA; Hsieh, JJ; Joshi, S; Tolkunov, D; White, E; Yao, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.22) | 29.6817 |
| 2010's | 33 (73.33) | 24.3611 |
| 2020's | 11 (24.44) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, FB | 2 |
| Marx, C | 1 |
| Spangel, SB | 2 |
| Thierbach, R | 2 |
| Zhu, L | 1 |
| Deng, Y | 1 |
| Ji, T | 1 |
| Zhou, H | 2 |
| Liu, W | 1 |
| Chen, Y | 1 |
| Li, M | 1 |
| Yang, Y | 1 |
| Lu, Y | 2 |
| Li, X | 2 |
| Cheng, L | 1 |
| Deepak, RNVK | 1 |
| Wang, G | 1 |
| Meng, Z | 1 |
| Tao, L | 1 |
| Xie, M | 1 |
| Chi, W | 1 |
| Zhang, Y | 1 |
| Yang, M | 1 |
| Liao, Y | 1 |
| Chen, R | 1 |
| Liang, Y | 1 |
| Zhang, J | 3 |
| Huang, Y | 3 |
| Wang, W | 1 |
| Guo, Z | 1 |
| Wang, Y | 1 |
| Lin, JD | 1 |
| Fan, H | 1 |
| Chen, L | 2 |
| Shankaraiah, RC | 1 |
| Callegari, E | 1 |
| Guerriero, P | 1 |
| Rimessi, A | 1 |
| Pinton, P | 1 |
| Gramantieri, L | 1 |
| Silini, EM | 1 |
| Sabbioni, S | 1 |
| Negrini, M | 1 |
| Dong, S | 1 |
| Ruiz-Calderon, B | 1 |
| Rathinam, R | 1 |
| Eastlack, S | 1 |
| Maziveyi, M | 1 |
| Alahari, SK | 1 |
| Kang, YT | 1 |
| Hsu, WC | 1 |
| Ou, CC | 1 |
| Tai, HC | 1 |
| Hsu, HT | 1 |
| Yeh, KT | 1 |
| Ko, JL | 1 |
| Zhang, Q | 1 |
| Sun, C | 1 |
| Wang, Q | 1 |
| Alcalá, S | 1 |
| Sancho, P | 3 |
| Martinelli, P | 2 |
| Navarro, D | 1 |
| Pedrero, C | 1 |
| Martín-Hijano, L | 1 |
| Valle, S | 1 |
| Earl, J | 1 |
| Rodríguez-Serrano, M | 1 |
| Ruiz-Cañas, L | 1 |
| Rojas, K | 1 |
| Carrato, A | 1 |
| García-Bermejo, L | 1 |
| Fernández-Moreno, MÁ | 1 |
| Hermann, PC | 2 |
| Sainz, B | 2 |
| Jones, GR | 1 |
| Molloy, MP | 1 |
| Jaromy, M | 1 |
| Miller, JD | 1 |
| Goebel, S | 1 |
| Leovsky, C | 1 |
| Hoelzer, D | 1 |
| Zhang, C | 2 |
| Hu, J | 1 |
| Sheng, L | 1 |
| Yuan, M | 1 |
| Wu, Y | 2 |
| Zheng, G | 1 |
| Qiu, Z | 1 |
| Zhou, X | 1 |
| Liu, S | 1 |
| Lin, X | 1 |
| Xu, L | 1 |
| Mao, X | 2 |
| Liu, J | 1 |
| Zhang, Z | 1 |
| Jiang, W | 2 |
| He, Y | 1 |
| Tai, S | 1 |
| Deng, M | 1 |
| Fan, Z | 1 |
| Ping, F | 1 |
| He, L | 1 |
| Cheng, B | 1 |
| Xia, J | 1 |
| Andersen, DK | 1 |
| Menendez, JA | 6 |
| Joven, J | 5 |
| Popovich, IG | 2 |
| Piskunova, TS | 1 |
| Tyndyk, ML | 2 |
| Anikin, IV | 1 |
| Zabezhinskiĭ, MA | 1 |
| Anisimov, VN | 3 |
| Quinn, BJ | 1 |
| Dallos, M | 1 |
| Kitagawa, H | 1 |
| Kunnumakkara, AB | 1 |
| Memmott, RM | 1 |
| Hollander, MC | 1 |
| Gills, JJ | 1 |
| Dennis, PA | 1 |
| Akinyeke, T | 1 |
| Matsumura, S | 1 |
| Wang, X | 1 |
| Schalfer, ED | 1 |
| Saxena, A | 1 |
| Yan, W | 1 |
| Logan, SK | 1 |
| Lonardo, E | 1 |
| Cioffi, M | 1 |
| Sanchez-Ripoll, Y | 1 |
| Trabulo, SM | 1 |
| Dorado, J | 1 |
| Balic, A | 1 |
| Hidalgo, M | 1 |
| Heeschen, C | 2 |
| Takahashi, H | 1 |
| Hosono, K | 1 |
| Endo, H | 1 |
| Nakajima, A | 1 |
| Bonini, MG | 1 |
| Gantner, BN | 1 |
| Doherty, JR | 1 |
| Yang, C | 1 |
| Scott, KE | 1 |
| Cameron, MD | 1 |
| Fallahi, M | 1 |
| Li, W | 1 |
| Hall, MA | 1 |
| Amelio, AL | 1 |
| Mishra, JK | 1 |
| Li, F | 1 |
| Tortosa, M | 1 |
| Genau, HM | 1 |
| Rounbehler, RJ | 1 |
| Dang, CV | 1 |
| Kumar, KG | 1 |
| Butler, AA | 1 |
| Bannister, TD | 1 |
| Hooper, AT | 1 |
| Unsal-Kacmaz, K | 1 |
| Roush, WR | 1 |
| Cleveland, JL | 1 |
| Cañamero, M | 1 |
| Madriles, F | 1 |
| Michl, P | 1 |
| Gress, T | 1 |
| de Pascual, R | 1 |
| Gandia, L | 1 |
| Guerra, C | 1 |
| Barbacid, M | 1 |
| Wagner, M | 1 |
| Vieira, CR | 1 |
| Aicher, A | 1 |
| Real, FX | 1 |
| Zhang, B | 1 |
| Liu, LL | 1 |
| Zhang, DH | 1 |
| Zabezhinski, MA | 1 |
| Egormin, PA | 1 |
| Yurova, MN | 1 |
| Semenchenko, AV | 1 |
| Panchenko, AV | 1 |
| Trashkov, AP | 1 |
| Vasiliev, AG | 1 |
| Khaitsev, NV | 1 |
| Zhu, Z | 1 |
| Thompson, MD | 1 |
| Echeverria, D | 1 |
| McGinley, JN | 1 |
| Thompson, HJ | 1 |
| Jia, Y | 1 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Zhou, W | 1 |
| He, S | 1 |
| Xu, X | 1 |
| Ren, G | 1 |
| Xu, G | 1 |
| Tian, K | 1 |
| Joshi, S | 1 |
| Tolkunov, D | 1 |
| Aviv, H | 1 |
| Hakimi, AA | 1 |
| Yao, M | 1 |
| Hsieh, JJ | 1 |
| Ganesan, S | 1 |
| Chan, CS | 1 |
| White, E | 1 |
| DePeralta, DK | 1 |
| Wei, L | 1 |
| Ghoshal, S | 1 |
| Schmidt, B | 1 |
| Lauwers, GY | 1 |
| Lanuti, M | 1 |
| Chung, RT | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Cuyàs, E | 1 |
| Fernández-Arroyo, S | 1 |
| Alarcón, T | 1 |
| Lupu, R | 2 |
| Monji, K | 1 |
| Uchiumi, T | 1 |
| Hoshizawa, S | 1 |
| Yagi, M | 1 |
| Matsumoto, T | 1 |
| Setoyama, D | 1 |
| Matsushima, Y | 1 |
| Gotoh, K | 1 |
| Amamoto, R | 1 |
| Kang, D | 1 |
| Hirsch, HA | 2 |
| Iliopoulos, D | 2 |
| Tsichlis, PN | 1 |
| Struhl, K | 2 |
| Vakana, E | 1 |
| Altman, JK | 1 |
| Glaser, H | 1 |
| Donato, NJ | 1 |
| Platanias, LC | 1 |
| Mitra, S | 1 |
| Stemke-Hale, K | 1 |
| Mills, GB | 1 |
| Claerhout, S | 1 |
| Cufí, S | 4 |
| Oliveras-Ferraros, C | 4 |
| Martin-Castillo, B | 3 |
| Vellon, L | 2 |
| Vazquez-Martin, A | 4 |
| Del Barco, S | 1 |
| Bosch-Barrera, J | 1 |
| Man'cheva, TA | 1 |
| Demidov, DV | 1 |
| Plotnikova, NA | 1 |
| Kharitonova, TV | 1 |
| Pashkevich, IV | 1 |
| Shu, J | 1 |
| Fang, S | 1 |
| Teichman, PG | 1 |
| Xing, L | 1 |
| Huang, H | 1 |
| Brown, KA | 1 |
| Samarajeewa, NU | 1 |
| Simpson, ER | 1 |
| Economopoulou, P | 1 |
| Kaklamani, VG | 1 |
| Siziopikou, K | 1 |
| Lopez-Bonet, E | 1 |
| Corominas-Faja, B | 2 |
| Menendez, OJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis[NCT03525028] | 138 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for metformin and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Metformin, Microbiome and Protection Against Colorectal Cancer.
Topics: Animals; Anticarcinogenic Agents; Bacteria; Butyrates; Cell Transformation, Neoplastic; Colon; Color | 2021 |
Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Cell Proliferation; Cell Transforma | 2021 |
Diabetes and cancer: placing the association in perspective.
Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications | 2013 |
Colon epithelial proliferation and carcinogenesis in diet-induced obesity.
Topics: Aberrant Crypt Foci; Adiponectin; AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cell T | 2013 |
The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?
Topics: AMP-Activated Protein Kinases; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Tran | 2013 |
Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Transformation, Neoplastic; Female; Humans; M | 2012 |
Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Transformation, Neoplasti | 2011 |
Metformin: multi-faceted protection against cancer.
Topics: Cell Transformation, Neoplastic; Cellular Senescence; Diabetes Mellitus; DNA Damage; Epithelial-Mese | 2011 |
Endometrial carcinoma tumorigenesis and pharmacotherapy research.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Endom | 2012 |
Endocrine-related cancers and the role of AMPK.
Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm | 2013 |
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.
Topics: Aldehyde Dehydrogenase 1 Family; Breast Neoplasms; CD24 Antigen; Cell Differentiation; Cell Transfor | 2012 |
The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.
Topics: Acetyl-CoA Carboxylase; Animals; ATPase Inhibitory Protein; Cell Dedifferentiation; Cell Transformat | 2013 |
33 other studies available for metformin and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Butyrate and Metformin Affect Energy Metabolism Independently of the Metabolic Phenotype in the Tumor Therapy Model.
Topics: Animals; Butyrates; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Clone Cel | 2021 |
Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
Topics: Cell Transformation, Neoplastic; Chemoprevention; Humans; Leukoplakia, Oral; Metformin; Mouth Neopla | 2022 |
Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypog | 2022 |
Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Transformati | 2023 |
Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease M | 2019 |
Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
Topics: Animals; Antigens, Polyomavirus Transforming; Cell Transformation, Neoplastic; Female; Hypoglycemic | 2020 |
Metformin Mitigates Nickel-Elicited Angiopoietin-Like Protein 4 Expression via HIF-1α for Lung Tumorigenesis.
Topics: Angiopoietin-Like Protein 4; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cell Transformation, | 2020 |
Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer.
Topics: ADP-Ribosylation Factors; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2020 |
ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity.
Topics: Carcinoma, Pancreatic Ductal; Cell Line; Cell Plasticity; Cell Transformation, Neoplastic; Cytokines | 2020 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Topics: Adenosine Triphosphate; Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; Cell Line, Tumo | 2019 |
Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A.
Topics: A549 Cells; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Proli | 2019 |
Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carbon; Cell Transformation, | 2012 |
[Metformin effect on urethane-induced tumorigenesis in mice].
Topics: Adenoma; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinogens; Cell Transformation, N | 2012 |
Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogens; Cell Transformation, Neoplastic; Energy Metabol | 2013 |
Metformin targets c-MYC oncogene to prevent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Transfor | 2013 |
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.
Topics: Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease | 2013 |
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cluster | 2014 |
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Topics: Acinar Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Pancreatic Ductal; Cell D | 2014 |
Effects of metformin on FOXM1 expression and on the biological behavior of acute leukemia cell lines.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neopla | 2014 |
Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.
Topics: Aging; Animals; Animals, Newborn; Body Temperature; Body Weight; Cell Transformation, Neoplastic; Es | 2015 |
Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat.
Topics: Animals; Apoptosis; Blotting, Western; Buformin; Carcinogens; Cell Proliferation; Cell Transformatio | 2015 |
Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Colorect | 2015 |
The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.
Topics: Adenoma, Oxyphilic; AMP-Activated Protein Kinases; Autophagy; Carcinoma, Renal Cell; Cathepsins; Cel | 2015 |
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Hepatocellular; Cell Transformation, Neoplast | 2016 |
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.
Topics: BRCA1 Protein; Breast; Cell Line; Cell Transformation, Neoplastic; Energy Metabolism; Epithelial Cel | 2016 |
Serum depletion induced cancer stem cell-like phenotype due to nitric oxide synthesis in oncogenic HRas transformed cells.
Topics: Animals; Apoptosis; Biomarkers; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Line, Tumor; Ce | 2016 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineopl | 2011 |
Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice.
Topics: Animals; Antioxidants; Benzo(a)pyrene; Cell Transformation, Neoplastic; Female; Lipid Peroxidation; | 2011 |
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
Topics: Animals; Cell Differentiation; Cell Line; Cell Transformation, Neoplastic; Hypoglycemic Agents; Indu | 2012 |
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Transformation | 2013 |